BACKGROUND: Several studies of pediatric acute myeloid leukemia have described the various type-I or type-II aberrations and their relationship with clinical outcome. However, there has been no recent comprehensive overview of these genetic aberrations in one large pediatric acute myeloid leukemia cohort. DESIGN AND METHODS: We studied the different genetic aberrations, their associations and their impact on prognosis in a large pediatric acute myeloid leukemia series (n=506). Karyotypes were studied, and hotspot regions of NPM1, CEPBA, MLL, WT1, FLT3, N-RAS, K-RAS, PTPN11 and KIT were screened for mutations of available samples. The mutational status of all type-I and type-II aberrations was available in 330 and 263 cases, respectively. Survival analysis was performed in a subset (n=385) treated on consecutive acute myeloid leukemia Berlin-Frankfurt-Munster Study Group and Dutch Childhood Oncology Group treatment protocols. RESULTS: Genetic aberrations were associated with specific clinical characteristics, e.g. significantly higher diagnostic white blood cell counts in MLL-rearranged, WT1-mutated and FLT3-ITD-positive acute myeloid leukemia. Furthermore, there was a significant difference in the distribution of these aberrations between children below and above the age of two years. Non-random associations, e.g. KIT mutations with core-binding factor acute myeloid leukemia, and FLT3-ITD with t(15;17)(q22;q21), NPM1- and WT1-mutated acute myeloid leukemia, respectively, were observed. Multivariate analysis revealed a 'favorable karyotype', i.e. t(15;17)(q22;q21), t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22). NPM1 and CEBPA double mutations were independent factors for favorable event-free survival. WT1 mutations combined with FLT3-ITD showed the worst outcome for 5-year overall survival (22±14%) and 5-year event-free survival (20±13%), although it was not an independent factor in multivariate analysis. CONCLUSIONS: Integrative analysis of type-I and type-II aberrations provides an insight into the frequencies, non-random associations and prognostic impact of the various aberrations, reflecting the heterogeneity of pediatric acute myeloid leukemia. These aberrations are likely to guide the stratification of pediatric acute myeloid leukemia and may direct the development of targeted therapies.
BACKGROUND: Several studies of pediatric acute myeloid leukemia have described the various type-I or type-II aberrations and their relationship with clinical outcome. However, there has been no recent comprehensive overview of these genetic aberrations in one large pediatric acute myeloid leukemia cohort. DESIGN AND METHODS: We studied the different genetic aberrations, their associations and their impact on prognosis in a large pediatric acute myeloid leukemia series (n=506). Karyotypes were studied, and hotspot regions of NPM1, CEPBA, MLL, WT1, FLT3, N-RAS, K-RAS, PTPN11 and KIT were screened for mutations of available samples. The mutational status of all type-I and type-II aberrations was available in 330 and 263 cases, respectively. Survival analysis was performed in a subset (n=385) treated on consecutive acute myeloid leukemia Berlin-Frankfurt-Munster Study Group and Dutch Childhood Oncology Group treatment protocols. RESULTS: Genetic aberrations were associated with specific clinical characteristics, e.g. significantly higher diagnostic white blood cell counts in MLL-rearranged, WT1-mutated and FLT3-ITD-positive acute myeloid leukemia. Furthermore, there was a significant difference in the distribution of these aberrations between children below and above the age of two years. Non-random associations, e.g. KIT mutations with core-binding factor acute myeloid leukemia, and FLT3-ITD with t(15;17)(q22;q21), NPM1- and WT1-mutated acute myeloid leukemia, respectively, were observed. Multivariate analysis revealed a 'favorable karyotype', i.e. t(15;17)(q22;q21), t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22). NPM1 and CEBPA double mutations were independent factors for favorable event-free survival. WT1 mutations combined with FLT3-ITD showed the worst outcome for 5-year overall survival (22±14%) and 5-year event-free survival (20±13%), although it was not an independent factor in multivariate analysis. CONCLUSIONS: Integrative analysis of type-I and type-II aberrations provides an insight into the frequencies, non-random associations and prognostic impact of the various aberrations, reflecting the heterogeneity of pediatric acute myeloid leukemia. These aberrations are likely to guide the stratification of pediatric acute myeloid leukemia and may direct the development of targeted therapies.
Authors: Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Martin Zimmermann; Brian V Balgobind; Susan T C J M Arentsen-Peters; Marielle Alders; Andre Willasch; Gertjan J L Kaspers; Jan Trka; Andre Baruchel; Siebold S N de Graaf; Ursula Creutzig; Rob Pieters; Dirk Reinhardt; C Michel Zwaan Journal: Blood Date: 2009-01-26 Impact factor: 22.113
Authors: Jessica A Pollard; Todd A Alonzo; Robert B Gerbing; Phoenix A Ho; Rong Zeng; Yaddanapudi Ravindranath; Gary Dahl; Norman J Lacayo; David Becton; Myron Chang; Howard J Weinstein; Betsy Hirsch; Susana C Raimondi; Nyla A Heerema; William G Woods; Beverly J Lange; Craig Hurwitz; Robert J Arceci; Jerald P Radich; Irwin D Bernstein; Michael C Heinrich; Soheil Meshinchi Journal: Blood Date: 2010-01-07 Impact factor: 22.113
Authors: Michael H Tomasson; Zhifu Xiang; Richard Walgren; Yu Zhao; Yumi Kasai; Tracie Miner; Rhonda E Ries; Olga Lubman; Daved H Fremont; Michael D McLellan; Jacqueline E Payton; Peter Westervelt; John F DiPersio; Daniel C Link; Matthew J Walter; Timothy A Graubert; Mark Watson; Jack Baty; Sharon Heath; William D Shannon; Rakesh Nagarajan; Clara D Bloomfield; Elaine R Mardis; Richard K Wilson; Timothy J Ley Journal: Blood Date: 2008-02-12 Impact factor: 22.113
Authors: Ulrich Keilholz; Anne Letsch; Antonia Busse; Anne Marie Asemissen; Sandra Bauer; Igor Wolfgang Blau; Wolf-Karsten Hofmann; Lutz Uharek; Eckhard Thiel; Carmen Scheibenbogen Journal: Blood Date: 2009-04-23 Impact factor: 22.113
Authors: Brian V Balgobind; Pieter Van Vlierberghe; Ans M W van den Ouweland; H Berna Beverloo; Joan N R Terlouw-Kromosoeto; Elisabeth R van Wering; Dirk Reinhardt; Martin Horstmann; Gertjan J L Kaspers; Rob Pieters; C Michel Zwaan; Marry M Van den Heuvel-Eibrink; Jules P P Meijerink Journal: Blood Date: 2008-01-02 Impact factor: 22.113
Authors: Ina Radtke; Charles G Mullighan; Masami Ishii; Xiaoping Su; Jinjun Cheng; Jing Ma; Ramapriya Ganti; Zhongling Cai; Salil Goorha; Stanley B Pounds; Xueyuan Cao; Caroline Obert; Jianling Armstrong; Jinghui Zhang; Guangchun Song; Raul C Ribeiro; Jeffrey E Rubnitz; Susana C Raimondi; Sheila A Shurtleff; James R Downing Journal: Proc Natl Acad Sci U S A Date: 2009-07-27 Impact factor: 11.205
Authors: Li Li; Obdulio Piloto; Ho Bao Nguyen; Kathleen Greenberg; Kogo Takamiya; Frederick Racke; David Huso; Donald Small Journal: Blood Date: 2008-02-01 Impact factor: 22.113
Authors: I H I M Hollink; C M Zwaan; M Zimmermann; T C J M Arentsen-Peters; R Pieters; J Cloos; G J L Kaspers; S S N de Graaf; J Harbott; U Creutzig; D Reinhardt; M M van den Heuvel-Eibrink; C Thiede Journal: Leukemia Date: 2008-11-20 Impact factor: 11.528
Authors: Brian V Balgobind; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Rob Pieters; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; C Michel Zwaan; Marry M van den Heuvel-Eibrink Journal: Blood Date: 2009-06-15 Impact factor: 22.113
Authors: Phoenix A Ho; Todd A Alonzo; Robert B Gerbing; Jessica Pollard; Derek L Stirewalt; Craig Hurwitz; Nyla A Heerema; Betsy Hirsch; Susana C Raimondi; Beverly Lange; Janet L Franklin; Jerald P Radich; Soheil Meshinchi Journal: Blood Date: 2009-03-20 Impact factor: 22.113
Authors: Marjolein Blink; Marry M van den Heuvel-Eibrink; Valerie de Haas; Jan-Henning Klusmann; Henrik Hasle; C Michel Zwaan Journal: Haematologica Date: 2012-04 Impact factor: 9.941
Authors: Patricia Rubio; B Campos; J A Digiorge; M S Gallego; A Medina; J G Rossi; M S Felice; C N Alonso Journal: Int J Hematol Date: 2016-07-19 Impact factor: 2.490
Authors: Jasmijn D E de Rooij; Marry M van den Heuvel-Eibrink; Malou C H Hermkens; Lonneke J Verboon; Susan T C J M Arentsen-Peters; Maarten Fornerod; Andre Baruchel; Jan Stary; Dirk Reinhardt; Valerie de Haas; Rob Pieters; C Michel Zwaan Journal: Haematologica Date: 2015-01-16 Impact factor: 9.941
Authors: Jasmijn D E de Rooij; Eva Beuling; Marry M van den Heuvel-Eibrink; Askar Obulkasim; André Baruchel; Jan Trka; Dirk Reinhardt; Edwin Sonneveld; Brenda E S Gibson; Rob Pieters; Martin Zimmermann; C Michel Zwaan; Maarten Fornerod Journal: Haematologica Date: 2015-06-11 Impact factor: 9.941
Authors: E A Coenen; C M Zwaan; J Stary; A Baruchel; V de Haas; R W Stam; D Reinhardt; G J L Kaspers; S T C J M Arentsen-Peters; C Meyer; R Marschalek; L L Nigro; M Dworzak; R Pieters; M M van den Heuvel-Eibrink Journal: Leukemia Date: 2014-02-24 Impact factor: 11.528
Authors: Daria G Valerio; Jenny E Katsman-Kuipers; Joop H Jansen; Lonneke J Verboon; Valerie de Haas; Jan Stary; André Baruchel; Martin Zimmermann; Rob Pieters; Dirk Reinhardt; Marry M van den Heuvel-Eibrink; C Michel Zwaan Journal: Haematologica Date: 2014-05-09 Impact factor: 9.941
Authors: Hamid Bolouri; Jason E Farrar; Timothy Triche; Rhonda E Ries; Emilia L Lim; Todd A Alonzo; Yussanne Ma; Richard Moore; Andrew J Mungall; Marco A Marra; Jinghui Zhang; Xiaotu Ma; Yu Liu; Yanling Liu; Jaime M Guidry Auvil; Tanja M Davidsen; Patee Gesuwan; Leandro C Hermida; Bodour Salhia; Stephen Capone; Giridharan Ramsingh; Christian Michel Zwaan; Sanne Noort; Stephen R Piccolo; E Anders Kolb; Alan S Gamis; Malcolm A Smith; Daniela S Gerhard; Soheil Meshinchi Journal: Nat Med Date: 2017-12-11 Impact factor: 53.440
Authors: A M Aalbers; R T Calado; N S Young; C M Zwaan; C Wu; S Kajigaya; E A Coenen; A Baruchel; K Geleijns; V de Haas; G J L Kaspers; T W Kuijpers; D Reinhardt; J Trka; M Zimmermann; R Pieters; V H J van der Velden; M M van den Heuvel-Eibrink Journal: Leukemia Date: 2013-02-21 Impact factor: 11.528